Diabetes, obesity & metabolism · 2026
The One-Hour Oral Glucose Tolerance Test to Predict Glucose Intolerance Postpartum in Women With Prior Gestational Diabetes.
СтатьяМногоцентровое исследованиеРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bochanen Niels, Vanlaer Yana, Minschart Caro, Willems Maajke, Myngheer Nele, Maes Toon, van Pottelbergh Inge, Abrams Pascale, Vinck Wouter, Leuridan Liesbeth, Driessens Sabien, Billen Jaak, Laenen Annouschka, de Block Christophe, Benhalima Katrien
Аннотация
BACKGROUND: Women with prior gestational diabetes (GDM) are at higher risk of developing dysglycaemia postpartum. We evaluated whether the 1-h glucose on the postpartum OGTT predicts dysglycaemia and metabolic changes.
METHODS: Secondary analysis of a multicentre randomised controlled trial evaluating a mobile-based lifestyle intervention early postpartum in women with prediabetes after GDM (WHO 2013 criteria). Women were categorised by their 1-h glucose value at 3 months postpartum (baseline), using 8.6 mmol/L as the high-risk threshold following International Diabetes Federation criteria. A subgroup underwent a repeat OGTT at 12 months.
RESULTS: At 3 months postpartum, 28.0% (334/1193) had dysglycaemia based on the 2-h OGTT and 34.2% (408/1193) based on the 1-h glucose value. Women identified only by the 1-h glucose were less insulin resistant but showed similar β-cell dysfunction compared with those identified only by the 2-h OGTT. Among 166 women with baseline prediabetes defined by the 2-h OGTT, 63.9% (106) had 1-h glucose ≥ 8.6 mmol/L. At 1 year postpartum, women with baseline 1-h glucose ≥ 8.6 mmol/L accounted for all eight (7.3%) diagnoses of type 2 diabetes (p = 0.036), more dysglycaemia (61.5 vs. 40.4%, p = 0.010), greater β-cell impairment (lower ISSI-2, p = 0.001) and greater insulin resistance (lower Matsuda, p = 0.049) compared with those with 1-h glucose < 8.6 mmol/L.
CONCLUSION: In women with a recent history of GDM and subsequent prediabetes, a 1-h glucose value ≥ 8.6 mmol/L in early postpartum was associated with an increased risk for future type 2 diabetes, greater insulin resistance and impaired β-cell function, supporting its potential value as an early marker of metabolic risk.
TRIAL REGISTRATION: MELINDA Trial, NCT03559621.
METHODS: Secondary analysis of a multicentre randomised controlled trial evaluating a mobile-based lifestyle intervention early postpartum in women with prediabetes after GDM (WHO 2013 criteria). Women were categorised by their 1-h glucose value at 3 months postpartum (baseline), using 8.6 mmol/L as the high-risk threshold following International Diabetes Federation criteria. A subgroup underwent a repeat OGTT at 12 months.
RESULTS: At 3 months postpartum, 28.0% (334/1193) had dysglycaemia based on the 2-h OGTT and 34.2% (408/1193) based on the 1-h glucose value. Women identified only by the 1-h glucose were less insulin resistant but showed similar β-cell dysfunction compared with those identified only by the 2-h OGTT. Among 166 women with baseline prediabetes defined by the 2-h OGTT, 63.9% (106) had 1-h glucose ≥ 8.6 mmol/L. At 1 year postpartum, women with baseline 1-h glucose ≥ 8.6 mmol/L accounted for all eight (7.3%) diagnoses of type 2 diabetes (p = 0.036), more dysglycaemia (61.5 vs. 40.4%, p = 0.010), greater β-cell impairment (lower ISSI-2, p = 0.001) and greater insulin resistance (lower Matsuda, p = 0.049) compared with those with 1-h glucose < 8.6 mmol/L.
CONCLUSION: In women with a recent history of GDM and subsequent prediabetes, a 1-h glucose value ≥ 8.6 mmol/L in early postpartum was associated with an increased risk for future type 2 diabetes, greater insulin resistance and impaired β-cell function, supporting its potential value as an early marker of metabolic risk.
TRIAL REGISTRATION: MELINDA Trial, NCT03559621.